Literature DB >> 24504488

Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.

Gregor Thörmer1, Josephin Otto1, Lars-Christian Horn2, Nikita Garnov1, Minh Do3, Toni Franz3, Jens-Uwe Stolzenburg3, Michael Moche1, Thomas Kahn1, Harald Busse4.   

Abstract

BACKGROUND: Clinical management of prostate cancer increasingly aims to distinguish aggressive types that require immediate and radical treatment from indolent tumors that are candidates for watchful waiting. This requires reliable and reproducible parameters to effectively control potential cancer progression. Magnetic resonance imaging (MRI) may provide a non-invasive means for this purpose.
PURPOSE: To assess the value of diffusion-weighted imaging and proton MR spectroscopy for the prediction of prostate cancer (PCa) aggressiveness.
MATERIAL AND METHODS: In 39 of 64 consecutive patients who underwent endorectal 3-T MRI prior to radical prostatectomy, prostate specimens were analyzed as whole-mount step sections. Apparent diffusion coefficient (ADC), normalized ADC (nADC: tumor/healthy tissue), choline/citrate (CC), and (choline + creatine)/citrate (CCC) ratios were correlated with Gleason scores (GS) from histopathological results. The power to discriminate low (GS ≤ 6) from higher-risk (GS ≥ 7) tumors was assessed with receiver operating characteristics (area under the curve [AUC]). Resulting threshold values were used by a blinded reader to distinguish between aggressive and indolent tumors.
RESULTS: Ninety lesions (1 × GS = 5, 41 × GS = 6, 36 × GS = 7, 12 × GS = 8) were considered. nADC (AUC = 0.90) showed a higher discriminatory power than ADC (AUC = 0.79). AUC for CC and CCC were 0.73 and 0.82, respectively. Using either nADC < 0.46 or CCC > 1.3, as well as both criteria for aggressive PCa, the reader correctly identified aggressive and indolent tumors in 31 (79%), 28 (72%), and 33 of 39 patients (85%), respectively. Predictions of tumor aggressiveness from TRUS-guided biopsies were correct in 27 of 36 patients (75%).
CONCLUSION: The combination of a highly sensitive normalized ADC with a highly specific CCC was found to be well suited to prospectively estimate PCa aggressiveness with a similar diagnostic accuracy as biopsy results. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  MR diffusion/perfusion; MR spectroscopy; Magnetic resonance imaging (MRI); prostate; staging

Mesh:

Substances:

Year:  2014        PMID: 24504488     DOI: 10.1177/0284185113520311

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Prostate MRSI predicts outcome in radical prostatectomy patients.

Authors:  Kristen L Zakian; William Hatfield; Omer Aras; Kun Cao; Derya Yakar; Debra A Goldman; Chaya S Moskowitz; Amita Shukla-Dave; Yousef Mazaheri Tehrani; Samson Fine; James Eastham; Hedvig Hricak
Journal:  Magn Reson Imaging       Date:  2016-01-26       Impact factor: 2.546

2.  Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.

Authors:  Jorge Abreu-Gomez; Daniel Walker; Tareq Alotaibi; Matthew D F McInnes; Trevor A Flood; Nicola Schieda
Journal:  Eur Radiol       Date:  2020-03-24       Impact factor: 5.315

3.  Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping.

Authors:  Ananya Panda; Gregory OʼConnor; Wei Ching Lo; Yun Jiang; Seunghee Margevicius; Mark Schluchter; Lee E Ponsky; Vikas Gulani
Journal:  Invest Radiol       Date:  2019-08       Impact factor: 6.016

4.  The diagnostic accuracy of high b-value diffusion- and T2-weighted imaging for the detection of prostate cancer: a meta-analysis.

Authors:  Tom J Syer; Keith C Godley; Donnie Cameron; Paul N Malcolm
Journal:  Abdom Radiol (NY)       Date:  2018-07

5.  Three-dimensional nuclear magnetic resonance spectroscopy: a complementary tool to multiparametric magnetic resonance imaging in the identification of aggressive prostate cancer at 3.0T.

Authors:  Michael Deal; Florian Bardet; Paul-Michael Walker; Mathilde Funes de la Vega; Alexandre Cochet; Luc Cormier; Imad Bentellis; Romaric Loffroy
Journal:  Quant Imaging Med Surg       Date:  2021-08

6.  Evaluation of diffusion-weighted MRI and (18F) fluorothymidine-PET biomarkers for early response assessment in patients with operable non-small cell lung cancer treated with neoadjuvant chemotherapy.

Authors:  Dominic Carlin; Alexander Weller; Gem Kramer; Yan Liu; John C Waterton; Arturo Chiti; Martina Sollini; A Joop de Langen; Mary E R O'Brien; Maria Urbanowicz; Bart Km Jacobs; Nandita deSouza
Journal:  BJR Open       Date:  2019-07-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.